Research Opportunities for Reducing Racial Disparities in Kidney Disease

Advances in Renal Replacement Therapy

Volumn 11, Issue 1, 2004, Pages 59-65

  Hostetter, Thomas H ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Chronic kidney disease; Ethnicity; Health services; Race; Research

Indexed keywords

CAUCASIAN; HEALTH CARE DELIVERY; HEALTH SERVICE; HIGH RISK POPULATION; KIDNEY DISEASE; KIDNEY FAILURE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK FACTOR; UNITED STATES;

EID: 0842309847     PISSN: 10734449     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.arrt.2003.10.009     Document Type: Article

References (48)

1. Hostetter TH: Prevention of the development and progression of renal disease. J Am Soc Nephrol 14: S144-147, 2003
2. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 290:199-206, 2003
3. Harris M, Eastman R, Cowie C, et al: Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 22:403-408, 1999
4. Schneider EC, Zaslavsky AM, Epstein AM: Racial disparities in the quality of care for enrollees in medicare managed care. JAMA 287:1288-1294, 2002
5. Mainous AG 3rd, Gill JM: The lack of screening for diabetic nephropathy: Evidence from a privately insured population. Fam Med 33:115-119, 2001
6. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
7. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462, 1993
8. Jafar TH, Schmid CH, Levey AS: Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease. Ann Intern Med 137:298-299, 2002
9. Agodoa LY, Appel L, Bakris GL, et al: Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial. JAMA 285:2719-2728, 2001
10. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
11. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
12. Kasiske BL, Lakatua JD, Ma JZ, et al: A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function. Am J Kidney Dis 31:954-961, 1998
13. McClellan WM, Knight DF, Karp H, et al: Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients: important differences between practice and published guidelines. Am J Kidney Dis 29:368-375, 1997
14. Kinchen KS, Sadler J, Fink N, et al: The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 137:479-486, 2002
15. Tarver-Carr ME, Powe NR, Eberhardt MS, et al: Excess risk of chronic kidney disease among African-American versus white subjects in the United States: A population-based study of potential explanatory factors. J Am Soc Nephrol 13:2363-2370, 2002
16. Karter AJ, Ferrara A, Liu JY, et al: Ethnic disparities in diabetic complications in an insured population. JAMA 287:2519-2527, 2002
17. Appel LJ, Middleton J, Miller ER3rd, et al: The rationale and design of the AASK cohort study. J Am Soc Nephrol 14:S166-172, 2003
18. Feldman HI, Appel LJ, Chertow GM, et al: The Chronic Renal Insufficiency Cohort (CRIC) Study: Design and methods. J Am Soc Nephrol 14:S148-153, 2003
19. Ohmit SE, Flack JM, Peters RM, et al: Longitudinal Study of the National Kidney Foundation's (NKF) Kidney Early Evaluation Program (KEEP). J Am Soc Nephrol 14:S117-121, 2003
20. McClellan WM, Flanders WD: Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 14:S65-70, 2003
21. Hunsicker LG, Adler S, Caggiula A, et al: Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int 51:1908-1919, 1997
22. Sarnak MJ, Poindexter A, Wang SR, et al: Serum C-reactive protein and leptin as predictors of kidney disease progression in the Modification of Diet in Renal Disease Study. Kidney Int 62:2208-2215, 2002
23. Sarnak MJ, Wang SR, Beck GJ, et al: Homocysteine, cysteine, and B vitamins as predictors of kidney disease progression. Am J Kidney Dis 40:932-939, 2002
24. Freedman BI, Soucie JM, McClellan WM: Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol 8:1942-1945, 1997
25. Jurkovitz C, Franch H, Shoham D, et al: Family members of patients treated for ESRD have high rates of undetected kidney disease. Am J Kidney Dis 40:1173-1178, 2002
26. Kim S, Ohta K, Hamaguchi A, et al: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24:195-204, 1994
27. Suthanthiran M, Li B, Song JO, et al: Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 97:3479-3484, 2000
28. Suthanthiran M, Khanna A, Cukran D, et al: Transforming growth factor-beta 1 hyperexpression in African American end-stage renal disease patients. Kidney Int 53:639-644, 1998
29. Grim CE, Luft FC, Miller JZ, et al: Racial differences in blood pressure in Evans County, Georgia: Relationship to sodium and potassium intake and plasma renin activity. J Chronic Dis 33:87-94, 1980
30. Kahn T, Mohammad G, Bornia ME, et al: Control of plasma renin activity in chronic stable renal disease. J Lab Clin Med 85:637-644, 1975
31. Rosenberg ME, Smith LJ, Correa-Rotter R, et al: The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int 45:403-410, 1994
32. Mackie FF, Campbell DJ, Meyer TW: Intrarenal angiotensin and bradykinin peptide levels in the remnant kidney model of renal insufficiency. Kidney Int 59:1458-1465, 2001
33. Ibrahim HN, Hostetter TH: Aldosterone in renal disease. Curr Opin Nephrol Hypertens 12:159-164, 2003
34. Lin JL, Lin-Tan DT, Hsu KH, et al: Environmental lead exposure and progression of diabetes in patients without diabetes. N Engl J Med 348:277-286, 2003
35. Brenner BM, Garcia DL, Anderson S: Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1:335-347, 1988
36. Keller G, Zimmer G, Mall G, et al: Nephron number in patients with primary hypertension. N Engl J Med 348:101-108, 2003
37. Hughson M, Farris AB, Douglas-Denton R, et al: Glomerular number and size in autopsy kidneys: The relationship to birth weight. Kidney Int 63:2113-2122, 2003
38. David RJ, Collins JW Jr: Differing birth weight among infants of U.S.-born blacks, African-born blacks, and U.S.-born whites. N Engl J Med 337:1209-1214, 1997
39. Narkun-Burgess DM, Nolan CR, Norman JE, et al: Forty-five year follow-up after uninephrectomy. Kidney Int 43:1110-11115, 1993
40. Cooper RS, Kaufman JS, Ward R: Race and genomics. N Engl J Med 348:1166-1170, 2003
41. Burchard EG, Ziv E, Coyle N, et al: The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348:1170-1175, 2003
42. Genetic determinants of diabetic nephropathy: The family investigation of nephropathy and diabetes (FIND). J Am Soc Nephrol 14:S202-204, 2003
43. Haga SB, Venter JC: Genetics. FDA races in wrong direction. Science 301:466, 2003
44. Effect of enalapril old survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators: N Engl J Med 325:293-302, 1991
45. Exner DV, Dries DL, Domanski MJ, et al: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344: 1351-1357, 2001
46. Golan L, Birkmeyer JD, Welch HG: The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 131:660-667, 1999
47. Kiberd BA, Jindal KK: Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation. Am J Kidney Dis 31:49-54, 1998
48. Hostetter TH, Lising M: National kidney disease education program. J Am Soc Nephrol 14:S114-116, 2003